-+ 0.00%
-+ 0.00%
-+ 0.00%

Oculis To Report Topline Results Around Year-End 2026 From First Genotype-Guided Registrational Dry Eye Trial Of Licaminlimab, Now Fully Randomized With 176 Patients, Two-Thirds Carrying Target TNFR1 Variant

Benzinga·10/19/2026 06:30:34
Listen to the news

High-Responder Target Enrichment: 2/3 of the 176 enrolled patients carry the target TNFR1 genetic variant previously linked to enhanced clinical response in Phase 2 trials

Precision Medicine Approach in a Large Market: Licaminlimab is positioned as a potential first-in-class precision medicine for an estimated 1.5+ million patients in the U.S. with moderate-to-severe TNFR1-mediated dry eye disease (DED)1-4, addressing a critical unmet need in a historically heterogeneous indication.

Key Milestone on Track: Topline data from this first-ever genotype-guided registrational trial in DED are anticipated around year-end 2026